Dual Checkpoint Blockade Shows Durability in Advanced Gynecologic Clear Cell Carcinoma

A recent phase II basket trial (DART) has demonstrated clinically meaningful durability in a subset of patients with gynecologic clear cell carcinoma (CCC) treated with dual CTLA-4/PD-1 blockade, despite a modest overall response rate. The study, focusing on a challenging-to-treat cancer, highlights the potential of immunotherapy, particularly in ovarian CCC, while underscoring the need for biomarker-driven patient selection and further research.

Understanding Clear Cell Carcinoma

Gynecologic CCCs, affecting the ovary, endometrium, and cervix, are rare, aggressive cancers known for their resistance to traditional chemotherapy. Single-agent PD-1/PD-L1 blockade has shown limited efficacy, prompting investigation into combination approaches like dual checkpoint inhibition to enhance immune responses.

The DART Trial Design

The DART (SWOG S1609) trial was a multicenter, phase II basket trial evaluating nivolumab (240 mg IV q2 weeks) in combination with ipilimumab (1 mg/kg IV q6 weeks) in 32 evaluable patients with gynecologic CCC. Patients had been heavily pretreated, with one to eight prior lines of therapy, including prior PD-1 exposure in some cases. The primary endpoint was RECIST v1.1 overall response rate (ORR), with secondary endpoints including immune RECIST (iRECIST) ORR, progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR).

Key Findings: Durability Over Response Rate

The overall response rate (ORR) by RECIST criteria was 9.38% (3/32), comprising two complete responses (CRs) and one partial response (PR). Notably, both CRs were observed in patients with ovarian CCC and remained ongoing beyond three years. The iRECIST ORR was 12.5% (4/32), with one patient with cervical CCC achieving a lasting immune-confirmed PR of 26 months, associated with an overall survival of 32.0 months.

The clinical benefit rate (CBR), defined as CR/PR or stable disease lasting at least six months, was 21.88% (7/32). Median overall survival (OS) across the entire cohort was 21.7 months, with ovarian CCC demonstrating the clearest activity, including the durable CRs. Activity in endometrial CCC was limited.

Safety Profile

Grade ≥3 adverse events (AEs) potentially related to treatment occurred in 53% (17/32) of patients, leading to treatment discontinuation in 22% (7/32). No treatment-related deaths were reported. Common grade 3–4 events included transaminase elevations, anemia, and nausea, consistent with the known immune-toxicity profile of dual checkpoint therapy.

Implications and Future Directions

The DART trial suggests that while the overall response rate to dual CTLA-4/PD-1 blockade in gynecologic CCC is modest, a subset of patients, particularly those with ovarian CCC, can experience durable clinical benefit. This highlights the importance of identifying biomarkers to select patients most likely to respond to this treatment approach.

Future research should focus on:

• Biomarker-driven patient selection
• Translational studies to understand the immune correlates of response
• Optimization of dosing strategies to improve tolerability

Key Takeaways

• Dual CTLA-4/PD-1 blockade can induce durable responses in a subset of patients with gynecologic CCC.
• Ovarian CCC appears to be the most immunotherapy-responsive subtype.
• Durability of response, rather than response frequency, is a key indicator of therapeutic benefit.
• Further research is needed to identify biomarkers for patient selection and optimize treatment regimens.